Key Takeaways
- Seven measurable factors can be some of the main drivers of DSO valuation multiples: scale, EBITDA quality, provider concentration, hygiene economics, payer mix, geographic fit, and data transparency. Each factor can raise or lower enterprise value in a meaningful way.
- Crossing specific revenue and location thresholds can expand the buyer pool from regional DSOs to national, private-equity-backed consolidators, which often supports higher multiples and stronger deal terms.
- CPA-led EBITDA normalization can surface $80K–$300K+ in defensible add-backs. Clean, well-documented financials can reduce the risk of re-trading and support the upper end of the multiple range.
- Lowering owner production below 70% of collections, strengthening the hygiene department, and building a diversified, fee-for-service-heavy payer mix can be some of the fastest levers owners can pull before going to market.
- McLerran & Associates’ CPA-led valuation and competitive auction process has guided roughly 2,000 practice sales and approximately $2 billion in transaction volume. Schedule a free, confidential discovery call to see where your practice may sit on the current multiple spectrum.
Executive Summary: How Seven Factors Shape DSO Multiples
Based on McLerran & Associates’ experience across roughly 2,000 closed practice sales and approximately $2 billion in transaction volume, seven factors can be some of the most consequential drivers of where a practice lands within the current multiple range. The table below maps each factor to three practical dimensions: how it typically moves your multiple, what buyers tend to see when they evaluate it, and what McLerran’s transaction data suggests about its real-world impact.
| Factor | Typical Impact on Multiple | Buyer Perception | McLerran Insight |
|---|---|---|---|
| Practice Scale & Locations | Can expand the buyer pool and lift multiples materially as revenue and location count grow | More locations can signal platform potential and reduced single-site risk | Scale can be the single biggest lever. Crossing key revenue thresholds often opens new buyer tiers. |
| EBITDA Size & Quality | Larger, cleaner EBITDA can support higher multiples. Weak add-back defense can compress them. | Buyers pay for predictable, transferable earnings, not reported revenue alone. | CPA-led add-back analysis can routinely surface $80K–$300K+ in normalized earnings. |
| Provider Concentration & Associate Retention | Owner production above 90% of revenue can result in a valuation discount. | High owner dependence often shifts deal structure toward earnouts and escrow. | Distributed associate production can be one of the fastest levers to pull before going to market. |
| Hygiene & Recall Economics | Hygiene revenue above 30% of collections can support higher adjusted EBITDA multiples. | Strong hygiene can signal a stable, recurring patient base buyers feel comfortable underwriting. | Hygiene metrics are often among the first data points DSO buyers request in diligence. |
| Payer/Revenue Mix Stability | Heavy Medicaid concentration (50%+) can compress multiples. | Fee-for-service and PPO-weighted practices can support higher margins and broader buyer pools. | Payer mix can shape both the multiple and the number of buyers willing to bid. |
| Geographic & Strategic Fit | Sun Belt and high-growth markets can command premiums, while rural or saturated markets may not. | Location often determines whether a practice is a bolt-on or a platform anchor. | Geography interacts with every other factor. A strong practice in a challenging market can still face headwinds. |
| Data Transparency & Normalized Earnings | Clean, defensible financials can support the top of the multiple range. Opaque books often invite re-trading. | Buyers discount practices where earnings cannot be verified line by line. | Diligence-grade work completed up front can be one of the best protections against a deal being renegotiated down. |
Factor 1: Practice Scale & Locations
Impact on Multiple: Scale can be the most powerful single driver of DSO valuation multiples. Single-location add-on practices often transact in a lower multiple range. Multi-location platforms with shared management infrastructure can reach materially higher multiples, because the buyer pool can expand from regional DSOs to national, private-equity-backed consolidators as location count and revenue grow.
In McLerran’s closed transactions, crossing key revenue and location thresholds has repeatedly unlocked a new tier of competitive bidding. A practice that attracts 10 qualified offers instead of 3 often receives not only a higher price but also better terms, more favorable equity structures, and stronger negotiating leverage on earnout provisions.
How to Move This Lever:
- Add a second location before going to market if the timeline allows. Even one additional site with shared billing and management can shift buyer perception from add-on to platform candidate.
- Once multiple locations exist, document the shared infrastructure, such as centralized scheduling, billing, and HR, that connects them. Buyers tend to distinguish between true platforms with operational integration and loose collections of siloed sites.
- As that multi-location infrastructure develops, focus on growing total collections toward the next buyer-pool threshold. Crossing $1.5M, $2M, and $4M+ in revenue can widen the competitive field that your documented platform can attract.
Factor 2: EBITDA Size & Quality
Impact on Multiple: EBITDA size often determines which buyer pool a practice enters. EBITDA quality often determines where inside that pool’s multiple range the practice lands. A $1M EBITDA practice with strong recurring hygiene production, a clean payer mix, and documented operational KPIs can transact near the upper end of its multiple band. The same EBITDA with provider-dependent revenue and limited documentation tends to land near the lower end.
EBITDA normalization, which means adjusting reported financials to reflect true, transferable profitability, can be where much of the value is created or lost before a deal even reaches the market. For $1M+ EBITDA practices, the add-back potential noted earlier often comes primarily from a single source: normalized owner-doctor compensation. Adjusting an owner’s above-market salary to replacement-doctor rates can account for most of that $80K–$300K range. Additional categories such as family-member payroll above market rates, personal vehicle expenses, and non-recurring professional fees, when properly documented, can further increase adjusted EBITDA.
How to Move This Lever:
- Work with a CPA-led advisor to identify and document every defensible add-back before going to market, rather than after a buyer’s quality-of-earnings team begins asking questions.
- Recognize that the largest single add-back in many practices is owner compensation normalization. Adjust salary to a market-rate replacement-doctor figure, typically 28–32% of production for general dentistry, so buyers can underwrite what the practice may earn after you exit.
- Beyond compensation, remove or properly document personal expenses run through the practice P&L. Undocumented items that remain into diligence can invite buyer skepticism and re-trading that erodes the value created by your CPA work.
Factor 3: Provider Concentration & Associate Retention
Impact on Multiple: Provider concentration, meaning the degree to which one doctor generates most clinical revenue, can be one of the most significant valuation risks in a DSO transaction. A practice where one provider produces 60% or more of collections can face a key-person discount that reduces enterprise value by 15–25% compared with practices that spread production across 3 or more providers.
Owner-doctor production below 70% of chair time can support a meaningful multiple uplift. Practices where the owner performs 90% or more of production often face a valuation reduction and may shift from platform DSO bidding to individual dentist or add-on buyer pools. Associate retention, including whether existing associates are under long-term agreements and producing consistently, is evaluated alongside concentration risk.
How to Move This Lever:
- Hire and retain at least 1 producing associate before going to market. Adding even 1 producing associate can move an owner-dependent practice up a full turn of EBITDA, because buyers tend to pay more for collections that transfer cleanly after the sale.
- Execute written associate employment agreements with reasonable non-compete and non-solicitation provisions.
- Begin stepping out of the chair gradually. Reducing your production share over 12–24 months before a sale can demonstrate transferability to buyers.
Factor 4: Hygiene & Recall Economics
Impact on Multiple: A strong hygiene department often signals something DSO buyers value highly: a stable, recurring patient base that is likely to remain after the selling dentist exits. Hygiene production can support higher valuation multiples when it reflects recurring patient demand, stable reappointment metrics, consistent recall behavior, and sustainable margin contribution that increases confidence in transferable patient flow.
Buyers commonly evaluate hygienist production per hour, reappointment rates, and active patient count trends. Weak performance in these areas can be treated as an attrition risk that compresses valuation multiples.
How to Move This Lever:
- Track and document hygiene production as a percentage of total collections. Many buyers associate the 25–35% range with a healthy recurring revenue base.
- Implement and document a structured recall system with measurable reappointment rates. Buyers typically prefer data over anecdotes.
- Address hygienist staffing gaps before going to market. An understaffed hygiene department can signal unmet demand that buyers may price as a risk rather than an opportunity.
Factor 5: Payer/Revenue Mix Stability
Impact on Multiple: Payer mix, meaning the breakdown of revenue across fee-for-service, PPO insurance, HMO insurance, and Medicaid, can be one of the main valuation variables after practice size. A fee-for-service practice and a Medicaid-heavy practice with identical revenue often are not worth the same to buyers, because reimbursement predictability and margin per chair can differ significantly.
Many buyers, especially private-equity-backed DSO groups, apply valuation discounts to practices with significant Medicaid exposure. In many transactions, buyers prefer Medicaid to represent no more than about 10% of total collections, although acceptable levels can vary by market and reimbursement environment. Heavy Medicaid concentration can also narrow the buyer pool and reduce the competitive tension that tends to push prices up.
How to Move This Lever:
- Diversify payer mix over time by adding fee-for-service capacity or reducing dependence on any single payer that represents more than 20% of production.
- Document PPO fee schedules and renegotiate below-market contracts before going to market. Buyers typically underwrite reimbursement durability, not just current collections.
- Manage payer concentration risk. Three PPOs each under 20% of production are usually viewed more favorably than one PPO representing 40%.
Factor 6: Geographic & Strategic Fit
Impact on Multiple: Geography can shape both the multiple a practice may achieve and the number of buyers willing to compete for it. Individual dental deal multiples can vary by geography, with Sun Belt premiums often observed in active consolidation markets. A practice that fills a strategic gap in a buyer’s existing network, such as completing a geographic cluster, entering a new metro, or anchoring a new regional platform, can command a premium that a comparable practice in a saturated or rural market may not receive.
Strategic fit also includes factors beyond geography. A practice that aligns with a buyer’s existing specialty mix, patient demographic, or operational model can be worth more to that specific buyer. This dynamic is one reason a competitive process among multiple vetted buyers, rather than a one-off negotiation, can be the difference between a market multiple and a premium multiple.
How to Move This Lever:
- Identify which buyers are actively expanding in your market before going to market. Not all buyers value a given location equally.
- Work with an advisor who maintains active relationships across the national buyer pool, so your practice reaches every buyer for whom it may represent a strategic fit.
- Avoid self-selecting out of the DSO market based on geography alone. McLerran’s national footprint, with offices in Cleveland, Atlanta, Northern Virginia, Los Angeles, and Phoenix, means local market intelligence can inform every engagement.
Factor 7: Data Transparency & Normalized Earnings
Impact on Multiple: Clean, defensible financials often form the foundation on which every other factor is valued. Buyers of dental practices typically normalize EBITDA by adjusting reported figures for owner compensation above or below market rates, personal or discretionary expenses, non-recurring professional fees, under-market associate compensation, staffing gaps, and one-time items. The goal is to determine sustainable earnings that can support valuation multiples.
When a practice’s financials cannot be verified line by line, buyers often discount the multiple or shift consideration into escrow and earnouts to protect themselves. Diligence-grade work completed before the deal goes to market, rather than after a buyer’s quality-of-earnings team begins asking questions, can be one of the strongest protections against a deal being renegotiated down at a late stage.
How to Move This Lever:
- Reconcile production-to-collections data and confirm that practice management software reports match tax returns and P&L statements.
- Document every add-back with supporting evidence, such as bank statements, invoices, and payroll records, so buyers have limited grounds to dispute the normalization.
- Engage a CPA-led advisor to build the EBITDA analysis before going to market. A weak valuation often gets renegotiated down in diligence, while a defensible one is more likely to hold.
DSO Multiples vs. Private-Buyer Valuation: A Side-by-Side View
DSO buyers and individual dentist buyers often use different valuation frameworks, and for practices above $1.5M in revenue, that difference can be substantial.
DSO buyers typically value practices on a multiple of adjusted EBITDA. General dental practices that meet DSO acquisition criteria in 2026 can sell in a 5×–8× adjusted EBITDA range, with the high end often reserved for practices with diversified production, strong hygiene, and desirable locations. Specialty practices can command premiums above this range, depending on margins and patient lifetime value.
Individual dentist buyers, by contrast, usually finance through SBA or conventional lending and underwrite on a percentage of collections or seller’s discretionary earnings (SDE, meaning the total financial benefit available to a single owner-operator). Doctor-to-doctor dental transactions typically clear at 60–80% of net revenue, which can produce materially lower valuations than the same practice might achieve in a competitive DSO process, particularly for practices above $1.5M in revenue.
The gap often becomes widest for larger, more profitable practices. For smaller premier practices, roughly $1M to $1.5M in revenue, a well-run doctor-to-doctor sale can sometimes produce a comparable or even superior outcome on an after-tax, after-structure basis, especially when the seller prefers a clean exit and a short work-back period. McLerran’s side-by-side valuation methodology quantifies both outcomes for every client, so the choice can be made with data rather than guesswork.
DSO deals also tend to carry structural complexity that private-buyer deals do not. DSO acquisitions are almost never all-cash. Typical structures include cash at close plus rollover equity into the DSO’s holding company, along with earnouts and escrow. As a result, the headline multiple is not directly comparable to an all-cash doctor-to-doctor sale. Up to about 40% of a DSO deal can be paid in equity rather than cash, which is why McLerran helps clients evaluate the DSO itself as an investment before they accept any offer.
How McLerran Quantifies These Factors in Real Deals
McLerran & Associates is a dental-only, sell-side advisory firm that represents practice owners, not buyers. Each engagement begins with a CPA-led EBITDA analysis built from the ground up. McLerran remotely accesses the practice’s management software, pulls production and collections reports, cross-references them against tax returns and P&L statements, and reviews every discretionary, personal, and non-recurring expense to arrive at a defensible adjusted EBITDA figure. This diligence-grade work happens before the deal goes to market, so the number is more likely to hold when buyers scrutinize it and the deal is less likely to be renegotiated down later.
From that foundation, McLerran runs a structured, auction-style bid process, typically 45 to 60 days, among a vetted pool of well-qualified buyers. This process often generates around 10 offers per listing. The competitive tension that results can be the main mechanism that lifts valuations, and clients often achieve about 30% higher valuations than owners who sell on their own. Poorly run or undercapitalized buyers are removed from consideration before the process begins, so owners see the real market without exposure to bad actors.
Throughout diligence, McLerran provides quality-of-earnings defense by actively defending the EBITDA it underwrote when a buyer’s team attempts to challenge add-backs or re-trade the deal. The firm’s approximately 85–90% transaction rate, versus an industry norm closer to 35–40%, can reflect what happens when the homework is completed correctly up front and an experienced advocate manages the narrative through close.
Frequently Asked Questions
What is the difference between EBITDA and collections, and which one do DSO buyers use?
Collections represent the total revenue a practice receives from patients and insurers. EBITDA, which stands for earnings before interest, taxes, depreciation, and amortization, is a measure of operating profitability after expenses, adjusted to reflect what the practice might earn under new ownership. DSO buyers typically value practices on a multiple of adjusted EBITDA, not collections, because they are buying future earnings power rather than top-line revenue. Individual dentist buyers, by contrast, often anchor on a percentage of collections because they are financing through SBA or conventional lending and underwriting their own ability to service debt. For practices above roughly $1.5M in revenue, the EBITDA-based DSO framework can produce a materially higher valuation than the collections-based private-buyer framework, although the right answer depends on your specific numbers, which McLerran’s side-by-side valuation is designed to quantify.
How does provider concentration affect my deal structure, not just my multiple?
Provider concentration, meaning the degree to which the selling dentist generates most clinical revenue, can affect both the multiple a buyer is willing to pay and how they structure the deal. When owner production is high, buyers often shift consideration away from cash at close and toward earnouts, escrow holdbacks, and retention-linked equity to protect themselves against the risk that revenue leaves with the selling dentist. This structure can mean a high-concentration practice receives a lower headline multiple and less favorable terms, with less cash upfront and more tied to post-close performance. Reducing your production share before going to market, by hiring and retaining producing associates, can improve both the multiple and the structure of the deal you receive.
Is now a good time to sell, or should I wait for multiples to recover further?
Demand for premier, well-documented dental practices remains strong as of 2026, and valuations for Class A assets sit near historically attractive levels, although below the peak multiples observed in 2021 to 2022. The more practical question is whether your specific practice is positioned to attract competitive bidding today. A practice with strong hygiene metrics, distributed associate production, a clean payer mix, and defensible financials is generally well-positioned in the current market. A practice that needs 12 to 24 months of preparation work may benefit from waiting. McLerran can provide a candid assessment of where your practice stands, and if you are not ready, the firm can update your valuation for free a year later rather than encourage a deal before the timing feels right.
What is the difference between joint-venture equity and holding-company equity in a DSO deal?
In a DSO transaction, equity can be held at 2 levels. Joint-venture equity is ownership in the local practice entity. It typically generates distributions, meaning regular cash payments from practice profits, and can provide a more predictable income stream but with a lower ceiling on long-term upside. Holding-company equity is ownership in the DSO’s parent company. It usually does not generate distributions, but if the DSO grows and eventually recapitalizes or sells, the value of that equity can increase significantly. The right structure depends on your financial goals, your confidence in the DSO’s growth path, and how much liquidity you need at close. McLerran models both structures across multiple time horizons so you can compare real after-tax outcomes before accepting any offer.
Why does McLerran charge for its valuation when other firms offer free valuations?
Many free valuations function as lead-generation tools and rely on rough estimates that may not withstand buyer scrutiny. When a weak valuation enters diligence, buyers often challenge the add-backs, compress the EBITDA, and re-trade the deal down. The owner can walk away with less than expected. McLerran’s CPA-led EBITDA analysis is built as diligence-grade work that is designed to hold up under rigorous buyer review, with every add-back documented and every normalization supported. In one case, a free valuation pegged a practice at $2.5M. McLerran valued it at $4.5M, and it sold for $5.25M after a competitive process. In that context, the valuation fee functions less as a cost and more as the foundation on which the final outcome is built.
Conclusion: Use Your Seven Factors to Guide Timing and Strategy
DSO valuation multiples do not come from a single fixed market number. They arise from seven measurable, practice-specific factors, including scale, EBITDA quality, provider concentration, hygiene economics, payer mix, geographic fit, and data transparency. Each factor can be quantified, improved, and defended in a competitive process. Practice owners who tend to achieve the strongest outcomes usually understand these factors before they go to market, rather than after a buyer has already set the anchor.
McLerran & Associates’ track record, described earlier, reflects what can happen when careful preparation meets a structured process. Whether your path leads to a DSO affiliation, a doctor-to-doctor sale, or a decision to wait, the first step involves understanding where your practice stands today and what it may be worth in both markets.
